Trial Profile
Temodal Capsule All-Case-Registered Surveillance (Designated Drug Use Investigation) - Evaluation of The Safety and Efficacy of Temodal in Patients With Newly Diagnosed Malignant Glioma (Concomitant With Radiotherapy and Then as Monotherapy) and Relapsed Malignant Glioma (as Monotherapy)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 11 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Oct 2012 Planned end date changed from 1 Jul 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.